CLYM NASDAQ
Climb Bio, Inc.
1W: -6.2%
1M: -27.3%
3M: -17.6%
YTD: +191.7%
1Y: +455.3%
$10.94
-0.13 (-1.17%)
Weekly Expected Move ±8.9%
$9
$10
$11
$12
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (36)
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
10 small-cap healthcare stocks with the strongest momentum grades
Small-cap stocks with strong momentum grades and triple-digit YTD gains
Bank of New York Mellon Corp Takes $1.61 Million Position in Climb Bio, Inc. $CLYM
Climb Bio rises after early-stage trial data for kidney disease drug
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High – Should You Buy?
Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
Why Is Climb Bio Stock Gaining Friday?
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
Climb Bio raises $110M in private placement; shares up
Climb Bio raises $110M in private placement; shares up
Climb Bio raises $110M in private placement; shares up
Climb Bio raises $110M in private placement; shares up
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Buy” from Brokerages
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of “Buy” from Analysts
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings
Climb Bio (NASDAQ:CLYM) Shares Gap Up After Analyst Upgrade
Research Analysts Issue Forecasts for Climb Bio Q1 Earnings
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Moderate Buy” by Analysts
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Brokerages
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
Ra Capital Management, L.P. Buys 101,462 Shares of Climb Bio (NASDAQ:CLYM) Stock
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)